'Our Lives Are Worth Saving': A Race Against Time for Those with Friedreich's Ataxia
Imagine a life where every passing month and year brings a tangible loss of what makes you, you – your ability to move, to speak, to even swallow without a struggle. This is the stark reality for the approximately 200 individuals in Ireland living with Friedreich's Ataxia (FRDA), a rare and relentlessly progressive neurological disease. They are now making a passionate plea to the government: make the first-ever treatment for their condition available to them, and make it now.
But here's where it gets controversial... The drug in question, Skyclarys (omaveloxolone), has shown promise in slowing the progression of FRDA. Yet, a report from the National Centre for Pharmaeconomics (NCPE) in December recommended against reimbursing it, citing its exorbitant cost. This has left patients feeling like their lives are being reduced to mere numbers on a spreadsheet.
Emily Felix, a 28-year-old trainee solicitor from Co Kilkenny, bravely shares her personal battle. "I have so much to say, but physically, I'm very restrained," she confides. Each day, she experiences a decline in her mobility and neurological function. For Emily, and others like her, Skyclarys isn't just a drug; it's a lifeline. "Having this particular drug to pause the progression gives me time," she explains. "It gives me hope that when eventually a cure does come, I will be able to benefit from the cure, that it won't be too late for me."
Emily's speech is rapidly deteriorating, and she now uses a straw for drinking due to swallowing difficulties. In a poignant act of preservation, she's using a voice-banking app to save a digital copy of her own voice – a piece of herself for her family to hold onto. "How can someone put a number on someone's life?" she asks, her voice trembling with emotion. "Why is my life being reduced to a number on a spreadsheet?"
And this is the part most people miss... The NCPE's recommendation, which landed on Emily's birthday, felt like a cruel "slap in the face." It highlights a fundamental disconnect between the economic considerations of healthcare and the profound human cost of a devastating illness. Emily is fighting not just for her own future, but for the chance to see her hard work in pursuing her legal career come to fruition.
Professor Michael Barry, Clinical Director of the NCPE, acknowledges the drug's potential benefits, noting it can improve outcomes on a rating scale by 2.4 points out of 93. However, he points out the staggering price tag: approximately €280,000 per patient per year, with an estimated five-year budget impact of €130 million to €168 million. He states that a 90% price reduction would be needed for it to be considered cost-effective.
"There is a way to get medications reimbursed in this country, and that's to price them fairly," Professor Barry asserts. The final decision rests with the HSE leadership team, who consider a multitude of factors, including clinical need, cost-effectiveness, and available resources.
Meanwhile, Biogen, the manufacturer of Skyclarys, remains committed to engaging with health authorities. Neurologists like Dr. Richard Walsh describe Skyclarys as a "ground-breaking" and "exciting development," the first approved drug for FRDA in both the US and Europe. He emphasizes that for years, the only option was to document "relentless progression." Now, with this drug, the rate of progression of movement disability and coordination issues could be halved year on year, potentially making the difference between a patient being able to feed themselves or communicate effectively.
The HSE and Department of Health reiterate their commitment to ensuring value for taxpayer money, making decisions based on "objective, scientific and economic grounds." They confirm that Skyclarys is still under active consideration.
Emily's message is clear: she doesn't just want to survive; she wants to live. She dreams of traveling the world and experiencing life to its fullest. "Without urgent treatment," she concludes, "my life won’t be worth living."
What are your thoughts on the balance between the cost of life-saving medication and the government's responsibility to its citizens? Do you believe a price can truly be put on a human life? Share your agreement or disagreement in the comments below!
